Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis
Authors:
Open Access
- 23 March 2023
- journal article
- research article
- Published by Springer Nature in BioDrugs
- Vol. 37 (3) , 409-420
Abstract
Objective We aimed to assess whether the introduction of the first infliximab biosimilar was associated with changes in overall infliximab consumption (originator and biosimilars) and price changes to the originator infliximab. Methods An interrupted time series analysis using infliximab sales data from 2010 to 2020 from the IQVIA Multinational Integrated Data Analysis System for eight selected regions: Australia, Canada, Hong Kong, Korea, India, Japan, the UK, and the USA. Quarterly measures of infliximab consumption and list prices were respectively defined as the number of standard units (SU)/1000 inhabitants and as 2020 USA dollars (USD)/SU. Results Following the introduction of infliximab biosimilars, overall infliximab consumption increased in Australia [immediate change: 0.145 SU/1000 inhabitants (P = 0.014); long-term change: 0.022 SU/1000 inhabitants per quarter (P < 0.001)], Canada [immediate change 0.415 (P = 0.008)], the UK [long-term change 0.024 (P < 0.001)], and Hong Kong [immediate change: 0.042 (P < 0.001)]. The list price of originator infliximab also decreased following biosimilar introduction in Australia [immediate change: − 187.84 USD/SU (P < 0.001); long-term change − 6.46 USD/SU per quarter (P = 0.043)], Canada [immediate change: − 145.58 (P < 0.001)], the UK [immediate change: − 34.95 (P = 0.010); long-term change: − 4.77 (P < 0.001)], and Hong Kong [long-term change: − 4.065 (P = 0.046)]. Consumption and price changes were inconsistent in India, Japan, Korea, and the USA. Conclusions Introduction of the first infliximab biosimilar was not consistently associated with increased consumption across regions. Additional policy and healthcare system interventions to support biosimilar infliximab adoption are needed.Keywords
Funding Information
- NHMRC Project Grant (1157506, 1196900)
- RGC Early Career Scheme, University Grants Committee of Hong Kong (27603421)
- Enhanced Start-up Fund for new academic staff, LKS Faculty of Medicine, University of Hong Kong
- Internal Research Fund, Department of Medicine, School of Clinical Medicine, LKS Faculty of Medicine, University of Hong Kong.
This publication has 37 references indexed in Scilit:
- Impact of Infliximab and Etanercept Biosimilars on Biological Disease-Modifying Antirheumatic Drugs Utilisation and NHS Budget in the UKBioDrugs, 2017
- Pricing and Reimbursement of Biosimilars in Central and Eastern European CountriesFrontiers in Pharmacology, 2017
- Efficacy, safety and pharmacokinetics of biosimilars of anti-tumor necrosis factor-α agents in rheumatic diseases; A systematic review and meta-analysisJournal of Autoimmunity, 2017
- Policy options for pharmaceutical pricing and purchasing: issues for low- and middle-income countriesHealth Policy and Planning, 2014
- Inequities in access to biologic and synthetic DMARDs across 46 European countriesAnnals of the Rheumatic Diseases, 2014
- Use of Interrupted Time Series Analysis in Evaluating Health Care Quality ImprovementsAcademic Pediatrics, 2013
- Patient Preferences for Biologic Agents in Rheumatoid Arthritis: A Discrete-Choice ExperimentValue in Health, 2013
- Does the Market Share of Generic Medicines Influence the Price Level?PharmacoEconomics, 2011
- Use of Biologics in Rheumatoid Arthritis: Current and Emerging Paradigms of CareClinical Therapeutics, 2011
- A Simple, Positive Semi-Definite, Heteroskedasticity and Autocorrelation Consistent Covariance MatrixEconometrica, 1987